
Immunic talks vidofludimus calcium & patent milestone at ECTRIMS 2025
9/22/2025
0:00
7:29
Immunic Inc (NASDAQ:IMUX) president and chief operating officer Jason Tardio talked with Proactive's Stephen Gunnion about the company’s presence at the 41st Congress of ECTRIMS in Barcelona this week and the progress of its lead multiple sclerosis candidate, vidofludimus calcium.
Tardio explained that Immunic is showcasing one oral and four poster presentations, including late-breaking data from the Phase 2 CALLIPER study in progressive multiple sclerosis. He said, “We showed very strong signals for reduction in confirmed disability worsening … and of course, the medicine is also and continues to be very safe and well tolerated in this population.”
The CALLIPER trial assessed vidofludimus calcium in nearly 475 patients with both non-active secondary progressive MS and primary progressive MS. Tardio highlighted that the drug candidate showed promising effects on disability progression and MRI outcomes, addressing a high unmet need in this patient group.
Immunic was also granted its fifth MS-directed US patent for vidofludimus calcium, covering multiple dosage strengths and applications in progressive MS and providing intellectual property protection until 2041. According to Tardio, this further strengthens the company’s multilayered patent portfolio for vidofludimus calcium.
Looking ahead, Immunic plans end-of-Phase 2 discussions with both the FDA and EMA before moving toward a potential Phase 3 program in progressive MS. Top-line data from the ENSURE-1 and -2 studies in relapsing MS are expected by the end of 2026.
For more insights from Immunic and updates on the biotechnology sector, visit Proactive’s YouTube channel. Don’t forget to give the video a like, subscribe to the channel, and enable notifications so you never miss future content.
#ImmunicInc #MultipleSclerosis #VidofludimusCalcium #ECTRIMS2025 #BiotechNews #ClinicalTrials #MSResearch #PharmaInnovation #DrugDevelopment #PatentNews
More episodes from "Proactive - Interviews for investors"
Don't miss an episode of “Proactive - Interviews for investors” and subscribe to it in the GetPodcast app.